Randomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral stepdown clarithromycin for treatment of patients with mild to moderate community-acquired pneumonia requiring hospitalization

Detalhes bibliográficos
Autor(a) principal: Corrêa, João Carlos
Data de Publicação: 2003
Outros Autores: Badaró, Roberto José da Silva, Bumroongkit, Chaiwat, Mera, Jorge Raúl, Dolmann, Alberto Lorenzo, Martínez, Luis Guillermo Juárez, Mayrinck, Lusane Romero, Tamez, Ricardo, Yang, Joanna Y.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UFBA
Texto Completo: http://repositorio.ufba.br/ri/handle/ri/17525
Resumo: Texto completo: acesso restrito. p. 1453–1468
id UFBA-2_efaa94836c272a131820e13009324ea5
oai_identifier_str oai:repositorio.ufba.br:ri/17525
network_acronym_str UFBA-2
network_name_str Repositório Institucional da UFBA
repository_id_str 1932
spelling Corrêa, João CarlosBadaró, Roberto José da SilvaBumroongkit, ChaiwatMera, Jorge RaúlDolmann, Alberto LorenzoMartínez, Luis Guillermo JuárezMayrinck, Lusane RomeroTamez, RicardoYang, Joanna Y.Corrêa, João CarlosBadaró, Roberto José da SilvaBumroongkit, ChaiwatMera, Jorge RaúlDolmann, Alberto LorenzoMartínez, Luis Guillermo JuárezMayrinck, Lusane RomeroTamez, RicardoYang, Joanna Y.2015-05-04T15:33:10Z20030149-2918http://repositorio.ufba.br/ri/handle/ri/17525v. 25, n. 5Texto completo: acesso restrito. p. 1453–1468Background: Empiric therapy for community-acquired pneumonia (CAP) requires the use of antibiotics with activity against a broad spectrum of respiratory pathogens and suitable pharmacokinetic properties to simplify IV-to-oral step-down therapy switches. Objective: The aim of this study was to compare the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin with a standard regimen of IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral stepdown clarithromycin in patients with mild to moderate CAP requiring hospitalization. Methods: In a randomized, open-label, parallel-group, multicenter study, adults with CAP received 7 to 14 days of treatment with either IV gatifloxacin 400 mg QD with the stepdown option or IV ceftriaxone 1 or 2 g QD (with or without erythromycin 0.5 or 1 g QID or clarithromycin 500 mg BID) with the stepdown option. Results: One hundred seventy adults with CAP were included in the study. IV gatifloxacin was stepped down to oral gatifloxacin in 90.6% (View the MathML source) of patients; IV ceftriaxone was stepped down to oral clarithromycin in 87.1% (View the MathML source) of patients. Among clinically evaluable patients (n = 153), cure rates at 1 to 3 days after treatment were 97.4% in the gatifloxacin group (View the MathML source) and 90.9% in the ceftriaxone group (View the MathML source), with a 95% CI for the difference (−3.7% to 19.1%) indicating statistical equivalence. In patients in whom pathogens were isolated from pretreatment sputum cultures, bacteriologic eradication rates were 100.0% (View the MathML source) and 90.9% (View the MathML source), respectively. Both regimens were well tolerated; treatment-related adverse events occurred in 27.1% (View the MathML source) and 21.2% (View the MathML source) of patients, respectively. Conclusions: In the population studied, treatment with IV gatifloxacin with an option for oral stepdown gatifloxacin was as effective for achieving clinical cure as IV ceftriaxone (with or without concomitant IV erythromycin or clarithromycin) with an option for oral stepdown clarithromycin. Both regimens were well tolerated.Submitted by Edileide Reis (leyde-landy@hotmail.com) on 2014-01-08T12:17:40Z No. of bitstreams: 1 Roberto Badaró.pdf: 1206906 bytes, checksum: 3a95cd2750f59092c68ccd4d1f0e9c09 (MD5)Approved for entry into archive by Flávia Ferreira (flaviaccf@yahoo.com.br) on 2015-05-04T15:33:10Z (GMT) No. of bitstreams: 1 Roberto Badaró.pdf: 1206906 bytes, checksum: 3a95cd2750f59092c68ccd4d1f0e9c09 (MD5)Made available in DSpace on 2015-05-04T15:33:10Z (GMT). No. of bitstreams: 1 Roberto Badaró.pdf: 1206906 bytes, checksum: 3a95cd2750f59092c68ccd4d1f0e9c09 (MD5) Previous issue date: 2003http://dx.doi.org.ez10.periodicos.capes.gov.br/10.1016/S0149-2918(03)80132-7reponame:Repositório Institucional da UFBAinstname:Universidade Federal da Bahia (UFBA)instacron:UFBAGatifloxacinCeftriaxoneClarithromycinErythromycinCerythromycinCommunity-acquired pneumoniaTolerabilityRandomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral stepdown clarithromycin for treatment of patients with mild to moderate community-acquired pneumonia requiring hospitalizationClinical Therapeuticsinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article10000-01-01Brasilinfo:eu-repo/semantics/openAccessengORIGINALRoberto Badaró.pdfRoberto Badaró.pdfapplication/pdf1206906https://repositorio.ufba.br/bitstream/ri/17525/1/Roberto%20Badar%c3%b3.pdf3a95cd2750f59092c68ccd4d1f0e9c09MD51LICENSElicense.txtlicense.txttext/plain1345https://repositorio.ufba.br/bitstream/ri/17525/2/license.txtff6eaa8b858ea317fded99f125f5fcd0MD52TEXTRoberto Badaró.pdf.txtRoberto Badaró.pdf.txtExtracted texttext/plain40586https://repositorio.ufba.br/bitstream/ri/17525/3/Roberto%20Badar%c3%b3.pdf.txtaec48a8ac14db6ac1b17ab2a15505e6eMD53ri/175252022-08-08 13:17:47.633oai:repositorio.ufba.br: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Repositório InstitucionalPUBhttp://192.188.11.11:8080/oai/requestopendoar:19322022-08-08T16:17:47Repositório Institucional da UFBA - Universidade Federal da Bahia (UFBA)false
dc.title.pt_BR.fl_str_mv Randomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral stepdown clarithromycin for treatment of patients with mild to moderate community-acquired pneumonia requiring hospitalization
dc.title.alternative.pt_BR.fl_str_mv Clinical Therapeutics
title Randomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral stepdown clarithromycin for treatment of patients with mild to moderate community-acquired pneumonia requiring hospitalization
spellingShingle Randomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral stepdown clarithromycin for treatment of patients with mild to moderate community-acquired pneumonia requiring hospitalization
Corrêa, João Carlos
Gatifloxacin
Ceftriaxone
Clarithromycin
Erythromycin
Cerythromycin
Community-acquired pneumonia
Tolerability
title_short Randomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral stepdown clarithromycin for treatment of patients with mild to moderate community-acquired pneumonia requiring hospitalization
title_full Randomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral stepdown clarithromycin for treatment of patients with mild to moderate community-acquired pneumonia requiring hospitalization
title_fullStr Randomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral stepdown clarithromycin for treatment of patients with mild to moderate community-acquired pneumonia requiring hospitalization
title_full_unstemmed Randomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral stepdown clarithromycin for treatment of patients with mild to moderate community-acquired pneumonia requiring hospitalization
title_sort Randomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral stepdown clarithromycin for treatment of patients with mild to moderate community-acquired pneumonia requiring hospitalization
author Corrêa, João Carlos
author_facet Corrêa, João Carlos
Badaró, Roberto José da Silva
Bumroongkit, Chaiwat
Mera, Jorge Raúl
Dolmann, Alberto Lorenzo
Martínez, Luis Guillermo Juárez
Mayrinck, Lusane Romero
Tamez, Ricardo
Yang, Joanna Y.
author_role author
author2 Badaró, Roberto José da Silva
Bumroongkit, Chaiwat
Mera, Jorge Raúl
Dolmann, Alberto Lorenzo
Martínez, Luis Guillermo Juárez
Mayrinck, Lusane Romero
Tamez, Ricardo
Yang, Joanna Y.
author2_role author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Corrêa, João Carlos
Badaró, Roberto José da Silva
Bumroongkit, Chaiwat
Mera, Jorge Raúl
Dolmann, Alberto Lorenzo
Martínez, Luis Guillermo Juárez
Mayrinck, Lusane Romero
Tamez, Ricardo
Yang, Joanna Y.
Corrêa, João Carlos
Badaró, Roberto José da Silva
Bumroongkit, Chaiwat
Mera, Jorge Raúl
Dolmann, Alberto Lorenzo
Martínez, Luis Guillermo Juárez
Mayrinck, Lusane Romero
Tamez, Ricardo
Yang, Joanna Y.
dc.subject.por.fl_str_mv Gatifloxacin
Ceftriaxone
Clarithromycin
Erythromycin
Cerythromycin
Community-acquired pneumonia
Tolerability
topic Gatifloxacin
Ceftriaxone
Clarithromycin
Erythromycin
Cerythromycin
Community-acquired pneumonia
Tolerability
description Texto completo: acesso restrito. p. 1453–1468
publishDate 2003
dc.date.issued.fl_str_mv 2003
dc.date.accessioned.fl_str_mv 2015-05-04T15:33:10Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://repositorio.ufba.br/ri/handle/ri/17525
dc.identifier.issn.none.fl_str_mv 0149-2918
dc.identifier.number.pt_BR.fl_str_mv v. 25, n. 5
identifier_str_mv 0149-2918
v. 25, n. 5
url http://repositorio.ufba.br/ri/handle/ri/17525
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.country.fl_str_mv Brasil
dc.source.pt_BR.fl_str_mv http://dx.doi.org.ez10.periodicos.capes.gov.br/10.1016/S0149-2918(03)80132-7
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFBA
instname:Universidade Federal da Bahia (UFBA)
instacron:UFBA
instname_str Universidade Federal da Bahia (UFBA)
instacron_str UFBA
institution UFBA
reponame_str Repositório Institucional da UFBA
collection Repositório Institucional da UFBA
bitstream.url.fl_str_mv https://repositorio.ufba.br/bitstream/ri/17525/1/Roberto%20Badar%c3%b3.pdf
https://repositorio.ufba.br/bitstream/ri/17525/2/license.txt
https://repositorio.ufba.br/bitstream/ri/17525/3/Roberto%20Badar%c3%b3.pdf.txt
bitstream.checksum.fl_str_mv 3a95cd2750f59092c68ccd4d1f0e9c09
ff6eaa8b858ea317fded99f125f5fcd0
aec48a8ac14db6ac1b17ab2a15505e6e
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da UFBA - Universidade Federal da Bahia (UFBA)
repository.mail.fl_str_mv
_version_ 1808459468543885312